Antonio Cuneo

List of Publications by Year in Descending Order

121 papers	2,290 citations	24 h-index	45 g-index
134 ext. papers	2,819 ext. citations	4.2 avg, IF	4.03 L-index

#	Paper	IF	Citations
121	Prediction of outcomes in cll patients treated with ibrutinib: validation of current prognostic models and development of a simplified three-factor model.. *American Journal of Hematology*, **2022** ,	7.1	2
120	COVID-19 severity and mortality in patients with CLL: an update of the international ERIC and Campus CLL study. *Leukemia*, **2021**, 35, 3444-3454	10.7	11
119	Efficacy of Front-Line Ibrutinib Versus Fludarabine, Cyclophosphamide and Rituximab (FCR) in Patients with CLL. a Multicenter "Real-World" Study. *Blood*, **2021**, 138, 2641-2641	2.2	
118	Genomic and clinical findings in myeloid neoplasms with PDGFRB rearrangement. *Annals of Hematology*, **2021**, 101, 297	3	1
117	Treatment with ibrutinib does not induce a TP53 clonal evolution in chronic lymphocytic leukemia. *Haematologica*, **2021**,	6.6	1
116	INCB84344-201: Ponatinib and steroids in frontline therapy of unfit patients with Ph+ acute lymphoblastic leukemia. *Blood Advances*, **2021**,	7.8	5
115	Impact of comorbidities and body mass index on the outcome of polycythemia vera patients. *Hematological Oncology*, **2021**, 39, 409-418	1.3	3
114	Chromosome banding analysis and genomic microarrays are both useful but not equivalent methods for genomic complexity risk stratification in chronic lymphocytic leukemia patients. *Haematologica*, **2021**,	6.6	4
113	Efficacy of idelalisib and rituximab in relapsed/refractory chronic lymphocytic leukemia treated outside of clinical trials. A report of the Gimema Working Group. *Hematological Oncology*, **2021**, 39, 326-335	1.3	3
112	Ruxolitinib rechallenge in resistant or intolerant patients with myelofibrosis: Frequency, therapeutic effects, and impact on outcome. *Cancer*, **2021**, 127, 2657-2665	6.4	7
111	TH2/TH1 Shift Under Ibrutinib Treatment in Chronic Lymphocytic Leukemia. *Frontiers in Oncology*, **2021**, 11, 637186	5.3	4
110	TP53 disruption as a risk factor in the era of targeted therapies: A multicenter retrospective study of 525 chronic lymphocytic leukemia cases. *American Journal of Hematology*, **2021**, 96, E306-E310	7.1	3
109	Perspectives and Emotional Experiences of Patients With Chronic Myeloid Leukemia During ENESTPath Clinical Trial and Treatment-Free Remission: Rationale and Protocol of the Italian Substudy. *Frontiers in Oncology*, **2021**, 11, 638689	5.3	
108	The complex karyotype landscape in chronic lymphocytic leukemia allows to refine the risk of Richter syndrome transformation. *Haematologica*, **2021**,	6.6	8
107	Preexisting and treatment-emergent autoimmune cytopenias in patients with CLL treated with targeted drugs. *Blood*, **2021**, 137, 3507-3517	2.2	12
106	Prognostic Impact and Risk Factors of Infections in Patients with Chronic Lymphocytic Leukemia Treated with Ibrutinib. *Cancers*, **2021**, 13,	6.6	5
105	Optimal Management of Chronic Lymphocytic Leukemia and Economic Constraints. *Cancer Journal (Sudbury, Mass)*, **2021**, 27, 320-327	2.2	0

104	Survival risk score for real-life relapsed/refractory chronic lymphocytic leukemia patients receiving ibrutinib. A campus CLL study. *Leukemia*, **2021**, 35, 235-238	10.7	11
103	In chronic lymphocytic leukaemia, SLAMF1 deregulation is associated with genomic complexity and independently predicts a worse outcome. *British Journal of Haematology*, **2021**, 192, 1068-1072	4.5	3
102	Relapsed/refractory diffuse large B-cell lymphoma patients. A multicenter retrospective analysis of eligibility criteria for car-T cell therapy. *Leukemia and Lymphoma*, **2021**, 62, 828-836	1.9	4
101	Comparison of ibrutinib and idelalisib plus rituximab in real-life relapsed/resistant chronic lymphocytic leukemia cases. *European Journal of Haematology*, **2021**, 106, 493-499	3.8	1
100	Ruxolitinib discontinuation syndrome: incidence, risk factors, and management in 251 patients with myelofibrosis. *Blood Cancer Journal*, **2021**, 11, 4	7	16
99	Assessment of the 4-factor score: Retrospective analysis of 586 CLL patients receiving ibrutinib. A campus CLL study. *American Journal of Hematology*, **2021**, 96, E168-E171	7.1	5
98	COVID-19 and Chronic Lymphocytic Leukemia: Where We Stand Now. *Cancer Journal (Sudbury, Mass)*, **2021**, 27, 328-333	2.2	3
97	Management of chronic lymphocytic leukemia in Italy during a one year of the COVID-19 pandemic and at the start of the vaccination program. A Campus CLL report. *Hematological Oncology*, **2021**, 39, 570-574	1.3	2
96	Spontaneously reversible adrenal nodules in primary diffuse large B-cell testicular lymphoma mimicking an extranodal involvement: A case report. *Radiology Case Reports*, **2021**, 16, 2168-2173	1	1
95	COMPLEX KARYOTYPE IN UNFIT PATIENTS WITH CLL TREATED WITH IBRUTINIB AND RITUXIMAB. THE GIMEMA LLC1114 PHASE 2 STUDY. *Blood*, **2021**,	2.2	2
94	Continuous treatment with Ibrutinib in 100 untreated patients with TP53 disrupted chronic lymphocytic leukemia: A real-life campus CLL study.. *American Journal of Hematology*, **2021**,	7.1	3
93	Efficacy of Front-Line Ibrutinib and Rituximab Combination and the Impact of Treatment Discontinuation in Unfit Patients with Chronic Lymphocytic Leukemia: Results of the Gimema LLC1114 Study.. *Cancers*, **2021**, 14,	6.6	1
92	Chronic lymphocytic leukemia management in Italy during the COVID-19 pandemic: a Campus CLL report. *Blood*, **2020**, 136, 763-766	2.2	17
91	COVID-19 severity and mortality in patients with chronic lymphocytic leukemia: a joint study by ERIC, the European Research Initiative on CLL, and CLL Campus. *Leukemia*, **2020**, 34, 2354-2363	10.7	118
90	Risk factors for progression to blast phase and outcome in 589 patients with myelofibrosis treated with ruxolitinib: Real-world data. *Hematological Oncology*, **2020**, 38, 372-380	1.3	7
89	Biological and clinical implications of mutations in chronic lymphocytic leukemia. *Haematologica*, **2020**, 105, 448-456	6.6	35
88	Differential Treatment Strategy in Polycythemia Vera Patients with Stable Suboptimal Response to Hydroxyurea: Clinical Correlations and Impact on Survival. *Blood*, **2020**, 136, 17-18	2.2	0
87	Retrospective Real-Life Comparison of Obinutuzumab Plus Chlorambucil Versus Ibrutinib in Previously Untreated and Unfit Patients with Chronic Lymphocytic Leukemia without TP53 Disruptions. Interim Results from the Italian CLL Campus. *Blood*, **2020**, 136, 30-31	2.2	

86	Complex Karyotype Subtypes at Chronic Lymphocytic Leukemia Diagnosis Refine the Risk of Developing a Richter Syndrome. the Richter Syndrome Scoring System. *Blood*, **2020**, 136, 33-34	2.2	1
85	Worldwide Examination of Patients with CLL Hospitalized for COVID-19. *Blood*, **2020**, 136, 45-49	2.2	2
84	Ruxolitinib Rechallenge in Resistant/Intolerant MF Patients: Frequency, Therapeutic Effects, and Impact on Outcome. *Blood*, **2020**, 136, 49-50	2.2	
83	Modulated expression of adhesion, migration and activation molecules may predict the degree of response in chronic lymphocytic leukemia patients treated with ibrutinib plus rituximab. *Haematologica*, **2020**, 106, 1500-1503	6.6	1
82	Kevetrin induces apoptosis in TP53 wild-type and mutant acute myeloid leukemia cells. *Oncology Reports*, **2020**, 44, 1561-1573	3.5	1
81	Clinical Characteristics and Outcome of West Nile Virus Infection in Patients with Lymphoid Neoplasms: An Italian Multicentre Study. *HemaSphere*, **2020**, 4, e395	0.3	2
80	Life after ruxolitinib: Reasons for discontinuation, impact of disease phase, and outcomes in 218 patients with myelofibrosis. *Cancer*, **2020**, 126, 1243-1252	6.4	51
79	Right Atrium Mass Assessed with 18F-FDG PET/CT Scan Turns Out to Be an Uncommon Relapse of Testicular Diffuse Large B-cell Lymphoma: A Case Report. *Diagnostics*, **2020**, 10,	3.8	0
78	A Tangle of Genomic Aberrations Drives Multiple Myeloma and Correlates with Clinical Aggressiveness of the Disease: A Comprehensive Review from a Biological Perspective to Clinical Trial Results. *Genes*, **2020**, 11,	4.2	1
77	Efficacy of bendamustine and rituximab in unfit patients with previously untreated chronic lymphocytic leukemia. Indirect comparison with ibrutinib in a real-world setting. A GIMEMA-ERIC and US study. *Cancer Medicine*, **2020**, 9, 8468-8479	4.8	8
76	Validation of a survival-risk score (SRS) in relapsed/refractory CLL patients treated with idelalisib-rituximab. *Blood Cancer Journal*, **2020**, 10, 92	7	5
75	The combination of complex karyotype subtypes and IGHV mutational status identifies new prognostic and predictive groups in chronic lymphocytic leukaemia. *British Journal of Cancer*, **2019**, 121, 150-156	8.7	17
74	Impact of 2016 WHO diagnosis of early and overt primary myelofibrosis on presentation and outcome of 232 patients treated with ruxolitinib. *Hematological Oncology*, **2019**, 37, 418-423	1.3	2
73	Chronic Myeloid Leukemia Patient@ Voice About the Experience of Treatment-Free Remission Failure: Results From the Italian Sub-Study of ENESTPath Exploring the Emotional Experience of Patients During Different Phases of a Clinical Trial. *Frontiers in Psychology*, **2019**, 10, 329	3.4	4
72	A scoring system to predict the risk of atrial fibrillation in chronic lymphocytic leukemia. *Hematological Oncology*, **2019**, 37, 508-512	1.3	3
71	Risk Factors for Progression to Blast Phase and Outcome in 589 Patients with Myelofibrosis Treated with Ruxolitinib: Real-World Evidence. *Blood*, **2019**, 134, 4166-4166	2.2	
70	Chromosome Banding Analysis Versus Genomic Microarrays: A Comparison of Methods for Genomic Complexity Risk Stratification in Chronic Lymphocytic Leukemia Patients with Complex Karyotype. *Blood*, **2019**, 134, 4287-4287	2.2	1
69	Impact of Comorbidities and Body Mass Index in Patients with Polycythemia Vera: A PV-NET Real World Study. *Blood*, **2019**, 134, 4184-4184	2.2	

68	Clinical Outcomes Under Hydroxyurea and Impact of ELN Responses in Patients with Polycythemia Vera: A PV-NET Real World Study. *Blood*, **2019**, 134, 4174-4174	2.2	1
67	Management of adverse events associated with idelalisib treatment in chronic lymphocytic leukemia and follicular lymphoma: A multidisciplinary position paper. *Hematological Oncology*, **2019**, 37, 3-14	1.3	46
66	Cytogenetic complexity in chronic lymphocytic leukemia: definitions, associations, and clinical impact. *Blood*, **2019**, 133, 1205-1216	2.2	94
65	Impact of comorbidities and body mass index in patients with myelofibrosis treated with ruxolitinib. *Annals of Hematology*, **2019**, 98, 889-896	3	4
64	Practical management of ibrutinib in the real life: Focus on atrial fibrillation and bleeding. *Hematological Oncology*, **2018**, 36, 624-632	1.3	36
63	Efficacy of bendamustine and rituximab as first salvage treatment in chronic lymphocytic leukemia and indirect comparison with ibrutinib: a GIMEMA, ERIC and UK CLL FORUM study. *Haematologica*, **2018**, 103, 1209-1217	6.6	24
62	In chronic lymphocytic leukaemia with complex karyotype, major structural abnormalities identify a subset of patients with inferior outcome and distinct biological characteristics. *British Journal of Haematology*, **2018**, 181, 229-233	4.5	25
61	Epidemiology, outcome, and risk factors for infectious complications in myelofibrosis patients receiving ruxolitinib: A multicenter study on 446 patients. *Hematological Oncology*, **2018**, 36, 561	1.3	38
60	Efficacy and safety of ruxolitinib in intermediate-1 IPSS risk myelofibrosis patients: Results from an independent study. *Hematological Oncology*, **2018**, 36, 285-290	1.3	19
59	Increased SHISA3 expression characterizes chronic lymphocytic leukemia patients sensitive to lenalidomide. *Leukemia and Lymphoma*, **2018**, 59, 423-433	1.9	4
58	Reproducible diagnosis of chronic lymphocytic leukemia by flow cytometry: An European Research Initiative on CLL (ERIC) & European Society for Clinical Cell Analysis (ESCCA) Harmonisation project. *Cytometry Part B - Clinical Cytometry*, **2018**, 94, 121-128	3.4	86
57	Differences in presenting features, outcome and prognostic models in patients with primary myelofibrosis and post-polycythemia vera and/or post-essential thrombocythemia myelofibrosis treated with ruxolitinib. New perspective of the MYSEC-PM in a large multicenter study. *Seminars in Hematology*, **2018**, 55, 248-255	4	13
56	Pretreatment Health-Related Quality of Life Profile According to the EORTC QLQ-C30 in Patients with Myelodysplastic Syndromes (MDS): Analysis on 443 Lower-Risk MDS Patients. *Blood*, **2018**, 132, 2293-2293	2.2	1
55	A Scoring System to Predict the Risk of Atrial Fibrillation in Chronic Lymphocytic Leukemia and Its Validation in a Cohort of Ibrutinib-Treated Patients. *Blood*, **2018**, 132, 3118-3118	2.2	4
54	Biological significance and prognostic/predictive impact of complex karyotype in chronic lymphocytic leukemia. *Oncotarget*, **2018**, 9, 34398-34412	3.3	8
53	Prognostic Role of Neutrophil to Lymphocyte Ratio (NLR) in Myelofibrosis Patients Treated with Ruxolitinib: A Multi-Center Experience. *Blood*, **2018**, 132, 4303-4303	2.2	1
52	Durability of spleen response affects the outcome of ruxolitinib-treated patients with myelofibrosis: Results from a multicentre study on 284 patients. *Leukemia Research*, **2018**, 74, 86-88	2.7	14
51	Immunosuppressive Treg cells acquire the phenotype of effector-T cells in chronic lymphocytic leukemia patients. *Journal of Translational Medicine*, **2018**, 16, 172	8.5	17

50	The emerging role of GSK-3 in the pathobiology of classical Hodgkin lymphoma. *Histopathology*, **2017**, 71, 72-80	7.3	7
49	Plasma matrix metalloprotease 9 correlates with blood lymphocytosis, leukemic cell invasiveness, and prognosis in B-cell chronic lymphocytic leukemia. *Tumor Biology*, **2017**, 39, 1010428317694325	2.9	9
48	IFI16 reduced expression is correlated with unfavorable outcome in chronic lymphocytic leukemia. *Apmis*, **2017**, 125, 511-522	3.4	6
47	Chlorambucil plus rituximab as front-line therapy for elderly and/or unfit chronic lymphocytic leukemia patients: correlation with biologically-based risk stratification. *Haematologica*, **2017**, 102, e352-e355	6.6	7
46	BCR-ABL-specific T-cell therapy in Ph+ ALL patients on tyrosine-kinase inhibitors. *Blood*, **2017**, 129, 582-586	2.2	38
45	An extensive molecular cytogenetic characterization in high-risk chronic lymphocytic leukemia identifies karyotype aberrations and TP53 disruption as predictors of outcome and chemorefractoriness. *Oncotarget*, **2017**, 8, 28008-28020	3.3	11
44	First Report of the Gimema LAL1811 Phase II Prospective Study of the Combination of Steroids with Ponatinib As Frontline Therapy of Elderly or Unfit Patients with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia. *Blood*, **2017**, 130, 99-99	2.2	47
43	Baseline factors associated with response to ruxolitinib: an independent study on 408 patients with myelofibrosis. *Oncotarget*, **2017**, 8, 79073-79086	3.3	38
42	Una Valutazione Economica Delle Sequenze Terapeutiche nel Trattamento di Prima Linea Della Leucemia Linfatica Cronica in Pazienti Unfit non Pretrattati. *Global & Regional Health Technology Assessment*, **2017**, 4, grhta.5000275	0.2	
41	Involvement of the P2X7-NLRP3 axis in leukemic cell proliferation and death. *Scientific Reports*, **2016**, 6, 26280	4.9	32
40	Complex chromosomal rearrangements leading to MECOM overexpression are recurrent in myeloid malignancies with various 3q abnormalities. *Genes Chromosomes and Cancer*, **2016**, 55, 375-88	5	3
39	Predictors for Response to Ruxolitinib in Real-Life: An Observational Independent Study on 408 Patients with Myelofibrosis. *Blood*, **2016**, 128, 1128-1128	2.2	4
38	Chlorambucil PLUS Rituximab As FRONT-LINE Therapy for Elderly and/or Unfit CLL Patients. LONG-TERM Follow-up and Correlation with Biologic-Based Risk Stratification. *Blood*, **2016**, 128, 3240-3240	2.2	
37	Identifying High-Risk Chronic Lymphocytic Leukemia: A Pathogenesis-Oriented Appraisal of Prognostic and Predictive Factors in Patients Treated with Chemotherapy with or without Immunotherapy. *Mediterranean Journal of Hematology and Infectious Diseases*, **2016**, 8, e2016047	3.2	5
36	Ibrutinib synergizes with MDM-2 inhibitors in promoting cytotoxicity in B chronic lymphocytic leukemia. *Oncotarget*, **2016**, 7, 70623-70638	3.3	18
35	Extensive next-generation sequencing analysis in chronic lymphocytic leukemia at diagnosis: clinical and biological correlations. *Journal of Hematology and Oncology*, **2016**, 9, 88	22.4	26
34	Response to ibrutinib of refractory life-threatening autoimmune hemolytic anemia occurring in a relapsed chronic lymphocytic leukemia patient with 17p deletion. *Leukemia and Lymphoma*, **2016**, 57, 2685-8	1.9	14
33	Molecular prediction of durable remission after first-line fludarabine-cyclophosphamide-rituximab in chronic lymphocytic leukemia. *Blood*, **2015**, 126, 1921-4	2.2	167

32	Chromosome aberrations detected by conventional karyotyping using novel mitogens in chronic lymphocytic leukemia: Clinical and biologic correlations. *Genes Chromosomes and Cancer*, **2015**, 54, 818-26	5	27
31	The anti-leukemic activity of sodium dichloroacetate in p53mutated/null cells is mediated by a p53-independent ILF3/p21 pathway. *Oncotarget*, **2015**, 6, 2385-96	3.3	13
30	Chlorambucil plus rituximab with or without maintenance rituximab as first-line treatment for elderly chronic lymphocytic leukemia patients. *American Journal of Hematology*, **2014**, 89, 480-6	7.1	86
29	Modern treatment in chronic lymphocytic leukemia: impact on survival and efficacy in high-risk subgroups. *Cancer Medicine*, **2014**, 3, 555-64	4.8	17
28	Appropriate use of bendamustine in first-line therapy of chronic lymphocytic leukemia. Recommendations from SIE, SIES, GITMO Group. *Leukemia Research*, **2014**, 38, 1269-77	2.7	10
27	Fludarabine plus alemtuzumab (FA) front-line treatment in young patients with chronic lymphocytic leukemia (CLL) and an adverse biologic profile. *Leukemia Research*, **2014**, 38, 198-203	2.7	4
26	Endothelium-mediated survival of leukemic cells and angiogenesis-related factors are affected by lenalidomide treatment in chronic lymphocytic leukemia. *Experimental Hematology*, **2014**, 42, 126-36.e1	3.1	20
25	Genetic subclonal complexity and miR125a-5p down-regulation identify a subset of patients with inferior outcome in low-risk CLL patients. *Oncotarget*, **2014**, 5, 140-9	3.3	9
24	Sodium dichloroacetate exhibits anti-leukemic activity in B-chronic lymphocytic leukemia (B-CLL) and synergizes with the p53 activator Nutlin-3. *Oncotarget*, **2014**, 5, 4347-60	3.3	19
23	The p53 transcriptional pathway is preserved in ATMmutated and NOTCH1mutated chronic lymphocytic leukemias. *Oncotarget*, **2014**, 5, 12635-45	3.3	7
22	Hsa-miR-15a and Hsa-miR-16-1 expression is not related to proliferation centers abundance and other prognostic factors in chronic lymphocytic leukemia. *BioMed Research International*, **2013**, 2013, 715391	3	5
21	BCR/ABL1-positive acute lymphoblastic leukemia relapsing as BCR/ABL1-negative acute lymphoblastic leukemia. *Leukemia and Lymphoma*, **2013**, 54, 2065-7	1.9	1
20	SIE, SIES, GITMO updated clinical recommendations for the management of chronic lymphocytic leukemia. *Leukemia Research*, **2012**, 36, 459-66	2.7	6
19	Chromosome aberrations detected by conventional karyotyping using novel mitogens in chronic lymphocytic leukemia with "normal" FISH: correlations with clinicobiologic parameters. *Blood*, **2012**, 119, 2310-3	2.2	57
18	Treating Ph+ Acute Lymphoblastic Leukemia (ALL) in the Elderly: The Sequence of Two Tyrosine Kinase Inhibitors (TKI) (Nilotinib and Imatinib) Does Not Prevent Mutations and Relapse.. *Blood*, **2012**, 120, 2601-2601	2.2	4
17	MEDI-551, a Humanized Monoclonal Anti-CD19, in Adults with Relapsed or Refractory Advanced B-Cell Malignancies: Results From a Phase 1/2 Study. *Blood*, **2012**, 120, 3677-3677	2.2	3
16	Merkel-Cell Polyomavirus Is Rarely Associated to B-Chronic Lymphocytic Leukemia and Occurs Late in the Natural History of the Disease. *Blood*, **2012**, 120, 4578-4578	2.2	
15	In Vitro and in Vivo Evidence of an Anti-Angiogenic Effect of Lenalidomide in Chronic Lymphocytic Leukemia. *Blood*, **2012**, 120, 1782-1782	2.2	

14	A Prospective, Multi Center Phase II Study Evaluating Predictive Factors for Lenalidomide Treatment in Relapse or Refractory Chronic Lymphocytic Leukemia Patients (LE.P.RE.): Preliminary Results about the First 20 Enrolled Patients. *Blood*, **2011**, 118, 1782-1782	2.2	
13	Circulating endothelial cells in patients with chronic lymphocytic leukemia: clinical-prognostic and biologic significance. *Cancer*, **2010**, 116, 1926-37	6.4	26
12	Clinicobiologic importance of cytogenetic lesions in chronic lymphocytic leukemia. *Expert Review of Hematology*, **2009**, 2, 305-14	2.8	7
11	Chromosome 14q32 translocations involving the immunoglobulin heavy chain locus in chronic lymphocytic leukaemia identify a disease subset with poor prognosis. *British Journal of Haematology*, **2008**, 142, 529-37	4.5	69
10	Unfavourable Outcome and Heterogeneity of Partner Chromosomes in Chronic Lymphocytic Leukemia with 14q32/IGH Translocations.. *Blood*, **2007**, 110, 4686-4686	2.2	
9	Chromosome 9 and 22 Breakpoints Cluster Regions Definition of Deleted Sequences on der(9) in Chronic Myeloid Leukemia.. *Blood*, **2005**, 106, 4842-4842	2.2	
8	Heterogeneous Chromosomal Mechanisms Generating the 5?RUNX1/3?CBFA2T1 Gene in Acute Myeloid Leukemia.. *Blood*, **2004**, 104, 4272-4272	2.2	
7	Late appearance of the 11q22.3-23.1 deletion involving the ATM locus in B-cell chronic lymphocytic leukemia and related disorders. Clinico-biological significance. *Haematologica*, **2002**, 87, 44-51	6.6	30
6	Acute promyelocytic leukemia with additional chromosome abnormalities in a renal transplant case. *Annals of Hematology*, **2001**, 80, 246-50	3	8
5	Cytogenetics of hybrid acute leukemias. *Leukemia and Lymphoma*, **1995**, 18 Suppl 1, 19-23	1.9	4
4	Trisomy 12 in chronic lymphocytic leukemia and hairy cell leukemia: a cytogenetic and interphase cytogenetic study. *Leukemia and Lymphoma*, **1994**, 15, 167-72	1.9	16
3	Clinical review on features and cytogenetic patterns in adult acute myeloid leukemia with lymphoid markers. *Leukemia and Lymphoma*, **1993**, 9, 285-91	1.9	10
2	Distinct cytogenetic and clinicopathologic features in acute myeloid leukemia after occupational exposure to pesticides and organic solvents. *Cancer*, **1992**, 70, 77-85	6.4	40
1	Prognostic subgroups in B-cell chronic lymphocytic leukemia defined by specific chromosomal abnormalities. *New England Journal of Medicine*, **1990**, 323, 720-4	59.2	496